tetano
Editor, Senior Moderator
Front Immunol
. 2024 Feb 5:15:1344184.
doi: 10.3389/fimmu.2024.1344184. eCollection 2024. Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study
Alberto Vogrig[SUP] 1 2 [/SUP], Sara Tartaglia[SUP] 1 2 [/SUP], Marta Dentoni[SUP] 1 2 [/SUP], Martina Fabris[SUP] 3 [/SUP], Francesco Bax[SUP] 2 [/SUP], Marco Belluzzo[SUP] 4 [/SUP], Lorenzo Verriello[SUP] 4 [/SUP], Daniele Bagatto[SUP] 5 [/SUP], Matteo Gastaldi[SUP] 6 [/SUP], Pierluigi Tocco[SUP] 7 [/SUP], Marco Zoccarato[SUP] 8 [/SUP], Luigi Zuliani[SUP] 9 [/SUP], Andrea Pilotto[SUP] 10 11 12 [/SUP], Alessandro Padovani[SUP] 10 11 12 [/SUP], Macarena Villagrán-García[SUP] 13 14 [/SUP], Vincent Davy[SUP] 15 [/SUP], Gian Luigi Gigli[SUP] 1 2 [/SUP], Jérôme Honnorat[SUP] 13 14 [/SUP], Mariarosaria Valente[SUP] 1 2 [/SUP]
Affiliations
Background: COVID-19 vaccines have been approved due to their excellent safety and efficacy data and their use has also permitted to reduce neurological complications of SARS-CoV-2. However, clinical trials were underpowered to detect rare adverse events. Herein, the aim was to characterize the clinical spectrum and immunological features of central nervous system (CNS) immune-related events following SARS-CoV-2 vaccination.
Methods: Multicenter, retrospective, cohort study (December 1, 2020-April 30, 2022). Inclusion criteria were (1) de novo CNS disorders developing after SARS-CoV-2 vaccination (probable causal relationship as per 2021 Butler criteria) (2); evidence for an immune-mediated etiology, as per (i) 2016 Graus criteria for autoimmune encephalitis (AE); (ii) 2015 Wingerchuk criteria for neuromyelitis optica spectrum disorders; (iii) criteria for myelitis.
Results: Nineteen patients were included from 7 tertiary referral hospitals across Italy and France (one of them being a national referral center for AE), over almost 1 year and half of vaccination campaign. Vaccines administered were mRNA-based (63%) and adenovirus-vectored (37%). The median time between vaccination and symptoms onset was 14 days (range: 2-41 days). CSF was inflammatory in 74%; autoantibodies were detected in 5%. CSF cytokine analysis (n=3) revealed increased CXCL-10 (IP-10), suggesting robust T-cell activation. The patients had AE (58%), myelitis (21%), acute disseminated encephalomyelitis (ADEM) (16%), and brainstem encephalitis (5%). All patients but 2 received immunomodulatory treatment. At last follow-up (median 130 days; range: 32-540), only one patient (5%) had a mRS>2.
Conclusion: CNS adverse events of COVID-19 vaccination appear to be very rare even at reference centers and consist mostly of antibody-negative AE, myelitis, and ADEM developing approximately 2 weeks after vaccination. Most patients improve following immunomodulatory treatment.
Keywords: COVID-19; SARS-CoV-2; neurologic adverse events; neurological complications; vaccination; vaccine.
. 2024 Feb 5:15:1344184.
doi: 10.3389/fimmu.2024.1344184. eCollection 2024. Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study
Alberto Vogrig[SUP] 1 2 [/SUP], Sara Tartaglia[SUP] 1 2 [/SUP], Marta Dentoni[SUP] 1 2 [/SUP], Martina Fabris[SUP] 3 [/SUP], Francesco Bax[SUP] 2 [/SUP], Marco Belluzzo[SUP] 4 [/SUP], Lorenzo Verriello[SUP] 4 [/SUP], Daniele Bagatto[SUP] 5 [/SUP], Matteo Gastaldi[SUP] 6 [/SUP], Pierluigi Tocco[SUP] 7 [/SUP], Marco Zoccarato[SUP] 8 [/SUP], Luigi Zuliani[SUP] 9 [/SUP], Andrea Pilotto[SUP] 10 11 12 [/SUP], Alessandro Padovani[SUP] 10 11 12 [/SUP], Macarena Villagrán-García[SUP] 13 14 [/SUP], Vincent Davy[SUP] 15 [/SUP], Gian Luigi Gigli[SUP] 1 2 [/SUP], Jérôme Honnorat[SUP] 13 14 [/SUP], Mariarosaria Valente[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38375477
- PMCID: PMC10876052
- DOI: 10.3389/fimmu.2024.1344184
Background: COVID-19 vaccines have been approved due to their excellent safety and efficacy data and their use has also permitted to reduce neurological complications of SARS-CoV-2. However, clinical trials were underpowered to detect rare adverse events. Herein, the aim was to characterize the clinical spectrum and immunological features of central nervous system (CNS) immune-related events following SARS-CoV-2 vaccination.
Methods: Multicenter, retrospective, cohort study (December 1, 2020-April 30, 2022). Inclusion criteria were (1) de novo CNS disorders developing after SARS-CoV-2 vaccination (probable causal relationship as per 2021 Butler criteria) (2); evidence for an immune-mediated etiology, as per (i) 2016 Graus criteria for autoimmune encephalitis (AE); (ii) 2015 Wingerchuk criteria for neuromyelitis optica spectrum disorders; (iii) criteria for myelitis.
Results: Nineteen patients were included from 7 tertiary referral hospitals across Italy and France (one of them being a national referral center for AE), over almost 1 year and half of vaccination campaign. Vaccines administered were mRNA-based (63%) and adenovirus-vectored (37%). The median time between vaccination and symptoms onset was 14 days (range: 2-41 days). CSF was inflammatory in 74%; autoantibodies were detected in 5%. CSF cytokine analysis (n=3) revealed increased CXCL-10 (IP-10), suggesting robust T-cell activation. The patients had AE (58%), myelitis (21%), acute disseminated encephalomyelitis (ADEM) (16%), and brainstem encephalitis (5%). All patients but 2 received immunomodulatory treatment. At last follow-up (median 130 days; range: 32-540), only one patient (5%) had a mRS>2.
Conclusion: CNS adverse events of COVID-19 vaccination appear to be very rare even at reference centers and consist mostly of antibody-negative AE, myelitis, and ADEM developing approximately 2 weeks after vaccination. Most patients improve following immunomodulatory treatment.
Keywords: COVID-19; SARS-CoV-2; neurologic adverse events; neurological complications; vaccination; vaccine.